Baricitinib is an oral, selective inhibitor of Janus kinase (JAK) 1/JAK2 that transiently and
reversibly inhibits many proinflammatory cytokines. This mechanism is a key mediator in a …

Undoubtedly, diagnosing and managing infections is one of the most challenging issues for
orofacial clinicians. As a result of the diversity of symptoms, complicated behavior, and …

Background Systemic therapies are typically combined with topical corticosteroids for the
management of moderate-to-severe atopic dermatitis. Upadacitinib is an oral Janus kinase …

Increasing number of Janus kinase (JAK) inhibitors have been approved for chronic
haematopoietic neoplasms and inflammatory/autoimmune diseases. We aimed to assess …

Background Systemic atopic dermatitis treatments that have acceptable safety are needed.
Objective To evaluate the safety of the oral Janus kinase inhibitor upadacitinib in …

Atopic dermatitis (AD) is a skin immune-mediated inflammatory disease with a chronic-
recurrent course. Acute exacerbations or flares are an integral part of the AD course and are …

En la actualidad, las infecciones de piel y partes blandas forman parte de un alto porcentaje
de las consultas en salud. Estas van desde infecciones leves, donde el manejo se realiza …

To infect its human host, herpes simplex virus 1 (HSV-1) must overcome the protective
barriers of skin and mucosa. Here, we addressed whether pathological skin conditions can …

An increasing number of studies have reported that atypical hand, foot, and mouth disease
(HFMD) is becoming a new concern for children's health. At present, there is no official …

Although half of hypertensive patients have hypertensive parents, known hypertension-
related human loci identified by genome-wide analysis explain only 3% of hypertension …